Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma
- 19 November 2024
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 44 (7) , 427-438
Abstract
Osteosarcoma is a common primary malignant bone tumor in children and young adults, with limited progress in improving survival rates for metastatic or recurrent cases. Kinase inhibitors have emerged as potential treatments for osteosarcoma due to the critical role kinases play in regulating cellular networks. However, single-agent kinase inhibitors often face challenges due to the activation of compensatory oncogenic signaling pathways, which can undermine treatment efficacy. In this study, a combination screening of FDA-approved kinase inhibitors was conducted in osteosarcoma cells. We identified the combination of ALK inhibitor and FLT3 inhibitor as a potent kinase-based therapeutic strategy for osteosarcoma. Our results showed that the combinatorial treatment synergistically suppressed osteosarcoma in cell lines, patient-derived organoids, and xenograft models. Mechanistically, the inhibition of FLT3 significantly promoted the activation of ALK, which subsequently enhanced its downstream PI3K/Akt and MAPK signaling pathways. The combinatorial use of an ALK inhibitor could reverse this process. Thus, our study demonstrates that the cooperative blockade of FLT3 and ALK synergistically suppresses osteosarcoma, providing a potential alternative for its treatment.Keywords
This publication has 33 references indexed in Scilit:
- FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung CancerClinical Cancer Research, 2016
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- A New Bliss Independence Model to Analyze Drug Combination DataSLAS Discovery, 2014
- Ceritinib inALK-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Crenolanib is a selective type I pan-FLT3 inhibitorProceedings of the National Academy of Sciences, 2014
- Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of SeparationCancer Discovery, 2012
- Post-translational modifications in signal integrationNature Structural & Molecular Biology, 2010
- PTEN and the PI3-Kinase Pathway in CancerAnnual Review of Pathology: Mechanisms of Disease, 2009
- Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2002